264209-16-7

Basic information

• Product Name: 3-AMINO-5-CYCLOPENTYL-2H-PYRAZOLE
• Synonyms: 3-AMINO-5-CYCLOPENTYL-2H-PYRAZOLE;5-CYCLOPENTYL-2H-PYRAZOL-3-YLAMINE;1H-Pyrazol-3-amine,5-cyclopentyl-(9CI);5-Cyclopentyl-1H-pyrazol-3-ylaMine;1H-Pyrazol-3-aMine, 5-cyclopentyl-;5-Cyclopentyl-1H-pyrazol-3-aMine;3-Amino-5-cyclopentyl-1H-pyrazole
• CAS NO: 264209-16-7
• Molecular Formula: C₈H₁₃N₃
• Molecular Weight: 151.21
• Product Categories: CYCLOPENTANE
• Mol File: 264209-16-7.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 373.5°Cat760mmHg
• Flash Point: 207.5°C
• Appearance: /
• Density: 1.193g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.616
• Storage Temp.: 2-8°C(protect from light)
• PKA: 15.76±0.10(Predicted)
• CAS DataBase Reference: 3-AMINO-5-CYCLOPENTYL-2H-PYRAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-AMINO-5-CYCLOPENTYL-2H-PYRAZOLE(264209-16-7)
• EPA Substance Registry System: 3-AMINO-5-CYCLOPENTYL-2H-PYRAZOLE(264209-16-7)

Safety Data

• Hazardous Substances Data: 264209-16-7(Hazardous Substances Data)

Usage

Description

3-AMINO-5-CYCLOPENTYL-2H-PYRAZOLE is a heterocyclic chemical compound that is part of the pyrazole family. It features a five-membered ring structure with four carbon atoms and one nitrogen atom, and is distinguished by the presence of an amino group and a cyclopentyl group. 3-AMINO-5-CYCLOPENTYL-2H-PYRAZOLE serves as a crucial building block in the synthesis of pharmaceutical drugs, agrochemicals, and other organic compounds due to its unique structure and reactivity, making it an important intermediate in the production of a variety of chemical compounds.

Uses

Used in Pharmaceutical Industry:
3-AMINO-5-CYCLOPENTYL-2H-PYRAZOLE is used as a key intermediate in the synthesis of various pharmaceutical drugs. Its unique structure allows for the development of new drug candidates with potential therapeutic applications.
Used in Organic Synthesis:
In the field of organic synthesis, 3-AMINO-5-CYCLOPENTYL-2H-PYRAZOLE is utilized as a versatile building block for creating a wide range of organic compounds. Its reactivity and structural features make it suitable for the formation of complex molecular architectures.
Used in Agrochemical Industry:
3-AMINO-5-CYCLOPENTYL-2H-PYRAZOLE is also used as a starting material in the development of agrochemicals. Its incorporation into the molecular structures of these compounds can lead to the creation of new pesticides or herbicides with improved efficacy and selectivity.

InChI:InChI=1/C8H13N3/c9-8-5-7(10-11-8)6-3-1-2-4-6/h5-6H,1-4H2,(H3,9,10,11)

Upstream product

• 95882-33-0 3-cyclopentyl-3-oxopropanenitrile 

Downstream Products

• 1000895-30-6 2-chloro-N-(5-cyclopentyl-1H-pyrazol-3-yl)pyrimidin-4-amine 
• 1356003-24-1 C₁₁H₁₄N₄ 
• 1269515-90-3 N-(2-cyclopentylpyrazolo[1,5-a]pyrimidin-6-yl)-2,6-difluoro-3-(propylsulfonamido)benzamide 

Relevant articles and documents

Dual-inhibitors of N-Myc and AURKA as potential therapy for neuroendocrine prostate cancer

Resistance to androgen-receptor (AR) directed therapies is, among other factors, associated with Myc transcription factors that are involved in development and progression of many cancers. Overexpression of N-Myc protein in prostate cancer (PCa) leads to its transformation to advanced neuroendocrine prostate cancer (NEPC) that currently has no approved treatments. N-Myc has a short half-life but acts as an NEPC stimulator when it is stabilized by forming a protective complex with Aurora A kinase (AURKA). Therefore, dual-inhibition of N-Myc and AURKA would be an attractive therapeutic avenue for NEPC. Following our computer-aided drug discovery approach, compounds exhibiting potent N-Myc specific inhibition and strong anti-proliferative activity against several N-Myc driven cell lines, were identified. Thereafter, we have developed dual inhibitors of N-Myc and AURKA through structure-based drug design approach by merging our novel N-Myc specific chemical scaffolds with fragments of known AURKA inhibitors. Favorable binding modes of the designed compounds to both N-Myc and AURKA target sites have been predicted by docking. A promising lead compound, 70812, demonstrated low-micromolar potency against both N-Myc and AURKA in vitro assays and effectively suppressed NEPC cell growth.

MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN

Disclosed herein are compounds and compositions having potency in the modulation of Myc family proteins. Such compounds and compositions can be used in the treatment of proliferative diseases, such as cancer, or in the treatment of disease where modulation of Myc family proteins is desired. Also disclosed herein are methods of using said compounds and compositions.

AURORA KINASE INHIBITORS

Disclosed herein inter alia are compositions and methods useful in the treatment of cancer and for modulating the activity of Aurora A kinase and/or a Myc family protein.